16th Jun 2016 08:17
LONDON (Alliance News) - Contract research organisation Cyprotex PLC on Thursday said it has launched ChemTarget, a virtual screening tool for use in predicting biological target interaction based on chemical structure.
"These tools will provide valuable information for medicinal chemists and drug discovery teams which, in turn, can be used to prioritise chemical synthesis and in vitro testing," said Chief Executive Anthony Baxter.
Cyprotex shares were untraded on Thursday, having last traded at 112.75 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.